Shopping Cart 0
Cart Subtotal
USD 0

Anavex Life Sciences Corp (AVXL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The company's target indications include Alzheimer's disease, Parkinson's disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex's lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer's disease, Parkinson's disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.

Anavex Life Sciences Corp (AVXL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12

Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13

Licensing Agreements 14

Anavex Enters Into Licensing Agreement With Life Science Research Israel 14

Equity Offering 15

Anavex Life Sciences Plans to Raise up to USD50 Million in Public Offering of Shares 15

Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 16

Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 17

Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 18

Anavex Life Sciences Announces Private Placement Of Units For USD 2.6 Million 19

Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For USD 0.1 Million 20

Debt Offering 21

Anavex Life Sciences Completes Private Placement Of Debenture For USD 10 Million 21

Anavex Life Sciences Corp-Key Competitors 22

Anavex Life Sciences Corp-Key Employees 23

Anavex Life Sciences Corp-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 09, 2018: Anavex Life Sciences reports fiscal third quarter 2018 financial results 25

May 10, 2018: Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results 26

Feb 07, 2018: Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results 27

Dec 11, 2017: Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs 28

Aug 07, 2017: Anavex Reports Fiscal Third Quarter 2017 Financial Results 29

May 10, 2017: Anavex Reports Fiscal Second Quarter 2017 Financial Results 31

Feb 07, 2017: Anavex Reports Fiscal First Quarter 2017 Financial Results 32

Corporate Communications 33

Mar 05, 2018: Anavex Life Sciences Announces Management Changes 33

Jul 20, 2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board 34

Jul 20, 2017: Anavex Life Sciences appoints scientific advisory board member 35

May 01, 2017: Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs 36

Feb 13, 2017: Anavex Life Sciences Strengthens Board of Directors 37

Legal and Regulatory 38

Mar 30, 2017: Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit 38

Jan 03, 2017: Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit 39

Product News 40

Nov 21, 2017: Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor 40

08/29/2018: Anavex enrols first patient in Phase llb/lll trial of ANAVEX2-73 41

07/20/2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board 42

07/04/2018: Anavex secures approval to start Phase llb/lll trial of ANAVEX 2-73 43

Clinical Trials 44

Jul 25, 2018: Anavex Life Sciences presents new data identifying treatment response biomarkers in Alzheimer's Disease patients treated with investigational ANAVEX2-73 at 2018 Alzheimer's Association International Conference 44

Jul 09, 2018: Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX 2-73 for the Treatment of Parkinson's Disease Dementia 46

Apr 17, 2018: Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX2-73 in Parkinson's Disease Dementia and Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome 47

Mar 07, 2018: Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT) 48

Jan 16, 2018: Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX2-73 Published in The Journal of Clinical Hypertension 49

Nov 04, 2017: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer's Disease Treatment ANAVEX2-73 at 2017 Clinical Trials on Alzheimer's Disease Meeting 50

Oct 30, 2017: Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Conference 52

Oct 27, 2017: Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017 53

Oct 12, 2017: Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX2-73 in Mild-to-Moderate Alzheimer's Disease Patients 54

May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference 55

Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Anavex Life Sciences Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12

Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13

Anavex Enters Into Licensing Agreement With Life Science Research Israel 14

Anavex Life Sciences Plans to Raise up to USD50 Million in Public Offering of Shares 15

Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 16

Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 17

Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 18

Anavex Life Sciences Announces Private Placement Of Units For USD 2.6 Million 19

Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For USD 0.1 Million 20

Anavex Life Sciences Completes Private Placement Of Debenture For USD 10 Million 21

Anavex Life Sciences Corp, Key Competitors 22

Anavex Life Sciences Corp, Key Employees 23

Anavex Life Sciences Corp, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Anavex Life Sciences Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The company's target indications include Alzheimer's disease, Parkinson's disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex's lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer's disease, Parkinson's disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.

Anavex Life Sciences Corp (AVXL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12

Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13

Licensing Agreements 14

Anavex Enters Into Licensing Agreement With Life Science Research Israel 14

Equity Offering 15

Anavex Life Sciences Plans to Raise up to USD50 Million in Public Offering of Shares 15

Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 16

Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 17

Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 18

Anavex Life Sciences Announces Private Placement Of Units For USD 2.6 Million 19

Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For USD 0.1 Million 20

Debt Offering 21

Anavex Life Sciences Completes Private Placement Of Debenture For USD 10 Million 21

Anavex Life Sciences Corp-Key Competitors 22

Anavex Life Sciences Corp-Key Employees 23

Anavex Life Sciences Corp-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 09, 2018: Anavex Life Sciences reports fiscal third quarter 2018 financial results 25

May 10, 2018: Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results 26

Feb 07, 2018: Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results 27

Dec 11, 2017: Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs 28

Aug 07, 2017: Anavex Reports Fiscal Third Quarter 2017 Financial Results 29

May 10, 2017: Anavex Reports Fiscal Second Quarter 2017 Financial Results 31

Feb 07, 2017: Anavex Reports Fiscal First Quarter 2017 Financial Results 32

Corporate Communications 33

Mar 05, 2018: Anavex Life Sciences Announces Management Changes 33

Jul 20, 2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board 34

Jul 20, 2017: Anavex Life Sciences appoints scientific advisory board member 35

May 01, 2017: Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs 36

Feb 13, 2017: Anavex Life Sciences Strengthens Board of Directors 37

Legal and Regulatory 38

Mar 30, 2017: Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit 38

Jan 03, 2017: Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit 39

Product News 40

Nov 21, 2017: Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor 40

08/29/2018: Anavex enrols first patient in Phase llb/lll trial of ANAVEX2-73 41

07/20/2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board 42

07/04/2018: Anavex secures approval to start Phase llb/lll trial of ANAVEX 2-73 43

Clinical Trials 44

Jul 25, 2018: Anavex Life Sciences presents new data identifying treatment response biomarkers in Alzheimer's Disease patients treated with investigational ANAVEX2-73 at 2018 Alzheimer's Association International Conference 44

Jul 09, 2018: Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX 2-73 for the Treatment of Parkinson's Disease Dementia 46

Apr 17, 2018: Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX2-73 in Parkinson's Disease Dementia and Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome 47

Mar 07, 2018: Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT) 48

Jan 16, 2018: Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX2-73 Published in The Journal of Clinical Hypertension 49

Nov 04, 2017: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer's Disease Treatment ANAVEX2-73 at 2017 Clinical Trials on Alzheimer's Disease Meeting 50

Oct 30, 2017: Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Conference 52

Oct 27, 2017: Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017 53

Oct 12, 2017: Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX2-73 in Mild-to-Moderate Alzheimer's Disease Patients 54

May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference 55

Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Anavex Life Sciences Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12

Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13

Anavex Enters Into Licensing Agreement With Life Science Research Israel 14

Anavex Life Sciences Plans to Raise up to USD50 Million in Public Offering of Shares 15

Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 16

Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 17

Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 18

Anavex Life Sciences Announces Private Placement Of Units For USD 2.6 Million 19

Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For USD 0.1 Million 20

Anavex Life Sciences Completes Private Placement Of Debenture For USD 10 Million 21

Anavex Life Sciences Corp, Key Competitors 22

Anavex Life Sciences Corp, Key Employees 23

Anavex Life Sciences Corp, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Anavex Life Sciences Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.